Skip to main content

Advertisement

SpringerLink
Log in

Sunitinib and Thrombosis

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Goodman VL, Rock EP, Dagher R, Ramchandani RP, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007;13(5):1367–73.

    Article  PubMed  CAS  Google Scholar 

  2. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010;28(13):2280–5.

    Article  PubMed  CAS  Google Scholar 

  3. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–38.

    Article  PubMed  CAS  Google Scholar 

  4. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):1–3.

    Article  Google Scholar 

  5. Motzer RJ, Rini BI, Bukowski RM, Curti BD, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516–24.

    Article  PubMed  CAS  Google Scholar 

  6. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.

    Article  PubMed  CAS  Google Scholar 

  7. Minor DR. Risk of arterial thrombosis not increased by sorafenib or sunitinib. J Clin Oncol. 2010;28(30):e619.

    Article  PubMed  Google Scholar 

  8. Longeron MT, Kellehar F, McDermott D, et al. Ischaemic stroke in a patient on sunitinib. BMJ Case Rep. 2010. doi:10.1136/bcr.01.2009.1420. Published online.

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, New York Medical College, 95 Grasslands Road, Valhalla, NY, 10595, USA

    Raveen Deol & Ramandeep Sahni

  2. Department of Hematology/Oncology, New York Medical College, Munger Pavilion, Suite 250, 95 Grasslands Road, Valhalla, NY, 10595, USA

    Gurpreet Lamba & Bharat Kumar Malhotra

  3. Department of Internal Medicine, New York Medical College, 95 Grasslands Road, Valhalla, NY, 10595, USA

    Dhaval Shah

Authors
  1. Gurpreet Lamba
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raveen Deol
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dhaval Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ramandeep Sahni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bharat Kumar Malhotra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gurpreet Lamba.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lamba, G., Deol, R., Shah, D. et al. Sunitinib and Thrombosis. J Gastrointest Canc 43 (Suppl 1), 128–130 (2012). https://doi.org/10.1007/s12029-011-9315-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-011-9315-8

Keywords

Search

Navigation